RecruitingNCT06426953

Predictive Effect of TGF-β and INS-PI3K-AKT Related Proteins for POD in Diabetes Patients

Predictive Effect of TGF-β Combined With INS-PI3K-AKT Signaling Pathway Related Proteins (ADNP, MAP6, Pgc-1α) for POD in Diabetes Patients


Sponsor

Xie Kangjie

Enrollment

180 participants

Start Date

May 20, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

To investigate the relationship between POD, TGF-β and INS-PI3K-AKT signaling pathway related proteins (ADNP, MAP6, PGC-1α) in diabetic patients


Eligibility

Min Age: 65 Years

Inclusion Criteria4

  • Age ≥65 years
  • History of diabetes ≥2 years and Glycated hemoglobin ≥6.5% or no history of diabetes and normal blood glucose
  • The ASA rating is Class I to III
  • The elderly patients of limited thoracic and abdominal tumor surgery

Exclusion Criteria10

  • Refused to participate
  • Previous history of schizophrenia, epilepsy, Parkinson's disease
  • History of alcohol abuse or drug dependence
  • Patients with ASA grade IV and above
  • Severe visual or hearing impairment, can not cooperate with the completion of cognitive function tests
  • Participants in other clinical trials within the last two months
  • Patients with severe arrhythmia or cardiac dysfunction(EF<40%)
  • There was a clear history of neurological and psychiatric problems or long-term use of sedatives or antidepressants
  • History of cerebrovascular disease or brain surgery or trauma
  • Severe liver dysfunction (Child-Pugh class C) or severe renal dysfunction (requiring dialysis)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo intervention

No intervention


Locations(2)

The People's hospital of Qiannan

Duyun, Guizhou, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06426953


Related Trials